Modified Nivolumab-Ipilimumab Dosing Shows No Benefit in Advanced RCC
A modified dosing regimen of nivolumab-ipilimumab for patients with advanced RCC did not provide additional benefit compared with standard dosing.
Diagnosis & Disease Information
Statistical Index Suggests That Many ICI Trials Show Uncertain Clinical Benefit
The survival-inferred fragility index of phase 3 trials for immune checkpoint inhibitors suggests that, despite statistical significance, survival data do not show a robust clinical benefit.
Industry-Funded Study Suggests There Is No Association Between TCI Use and Increased Skin Cancer Risk in Atopic Dermatitis
Observational study design and conflicts of interest prevent researchers from determining whether the FDA-mandated black box warning is warranted.
Immunotherapy in mCRPC: Teasing Out the Right Dosing Schedule
The phase 2 Clinical Trial CheckMate 650 shows promise for some immunotherapy in subset of patients with advanced prostate cancer, but the toxicities are concerning.
Opposition to a European Patent for CAR-T Therapy: A Mechanism to Control High Drug Prices?
The nongovernmental organizations argued that patents for this CAR-T should never have been granted in the first place because the underlying technology is not novel.
Timing and Type of Prior Cancer Therapy May Influence Mortality in Patients With Cancer Diagnosed With COVID-19
“Immunotherapy-alone [patients] had similar rates of death compared with those not on treatment within the past year,” Dr Wise-Draper emphasized.
Skin Toxicity Program Can Positively Address EGFR Inhibitor-Related Skin Toxicities
Patients given prophylactic treatment were 94% less likely to require a first rescue treatment for rash and 74% less likely to require a second rescue treatment.
Immunotherapy Improves Survival Despite Brain Metastases
Immunotherapy improved median overall survival by 7.5 months regardless of what other treatments patients received.
A New Hope for IL-18 Therapy
Engineered cytokine evades the tumor’s defenses and boosts the production of stem-like polyfunctional T cells.
Mycobacterial Infection Risk With Immune Checkpoint Inhibitors
Using FAERS, study researchers identified reported cases of tuberculosis and atypical mycobacterial infection in patients who received ICIs.
- Loading...
Loading...
Next post in General Oncology
Loading... 
Loading...